Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 3/2016

Open Access 01-06-2016 | Personalized Medicine in Colorectal Cancer (D Cunningham and EC Smyth, Section Editors)

Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer

Authors: Donna M. Graham, Vicky M. Coyle, Richard D. Kennedy, Richard H. Wilson

Published in: Current Colorectal Cancer Reports | Issue 3/2016

Login to get access

Abstract

Development of colorectal cancer occurs via a number of key pathways, with the clinicopathological features of specific subgroups being driven by underlying molecular changes. Mutations in key genes within the network of signalling pathways have been identified; however, therapeutic strategies to target these aberrations remain limited. As understanding of the biology of colorectal cancer has improved, this has led to a move toward broader genomic testing, collaborative research and innovative, adaptive clinical trial design. Recent developments in therapy include the routine adoption of wider mutational spectrum testing prior to use of targeted therapies and the first promise of effective immunotherapy for colorectal cancer patients. This review details current biomarkers in colorectal cancer for molecular stratification and for treatment allocation purposes, including open and planned precision medicine trials. Advances in our understanding, therapeutic strategy and technology will also be outlined.
Literature
1.
Van Cutsem E et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–9.CrossRefPubMed
2.
Heinemann V et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75.CrossRefPubMed
3.
Schwartzberg LS et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240–7.CrossRefPubMed
4.
5.
Sorlie T et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.CrossRefPubMedPubMedCentral
6.
Shepherd FA et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32.CrossRefPubMed
7.
Camidge DR et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011–9.CrossRefPubMedPubMedCentral
8.
Sadanandam A et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619–25.CrossRefPubMedPubMedCentral
9.
Roepman P et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014;134(3):552–62.CrossRefPubMedPubMedCentral
10.
Marisa L et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10(5):e1001453.CrossRefPubMedPubMedCentral
11.
12.
13.
Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003;21(6):1174–9.CrossRefPubMed
14.
15.
Cannavo E et al. Characterization of the interactome of the human MutL homologues MLH1, PMS1, and PMS2. J Biol Chem. 2007;282(5):2976–86.CrossRefPubMed
16.
Nosho K et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222(4):350–66.CrossRefPubMedPubMedCentral
17.
Wang L et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res. 2003;63(17):5209–12.PubMed
18.
Kakar S et al. Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age. Cancer. 2003;97(6):1421–7.CrossRefPubMed
19.
20.
Elsayed FA et al. Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. Eur J Hum Genet. 2015;23(8):1080–4.CrossRefPubMedPubMedCentral
21.
Spier I et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer. 2015;137(2):320–31.CrossRefPubMed
22.
Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–18.CrossRefPubMed
23.
24.
Jover R et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut. 2006;55(6):848–55.CrossRefPubMedPubMedCentral
25.
Sinicrope FA et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013;31(29):3664–72.CrossRefPubMedPubMedCentral
26.
Zaanan A et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2010;21(4):772–80.CrossRefPubMed
27.
Des Guetz G et al. Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX. Anticancer Res. 2010;30(10):4297–301.PubMed
28.
Nopel-Dunnebacke S et al. Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy. Z Gastroenterol. 2014;52(12):1394–401.CrossRefPubMed
29.
Tougeron D et al. Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: An AGEO multicenter study. J Clin Oncol. 2014;32:5s. suppl; abstr 3508.CrossRef
30.
Tran B et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20):4623–32.CrossRefPubMedPubMedCentral
31.
Tentori L et al. Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. Int J Oncol. 2013;43(1):210–8.PubMed
32.
Takahashi M et al. MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem. 2011;286(14):12157–65.CrossRefPubMedPubMedCentral
33.
Schwitalle Y et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology. 2008;134(4):988–97.CrossRefPubMed
34.•
Llosa NJ et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51. This is the first demonstration of a link between a genetically defined subtype of cancer and its corresponding expression of immune checkpoints in the tumour microenvironment. The mismatch repair-deficient colorectal tumours selectively upregulate several checkpoint molecules that are targets of agents in early clinical trials.CrossRefPubMedPubMedCentral
35.
Galon J et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4.CrossRefPubMed
36.••
Le DT et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. This clinical trial demonstrates that patients with microsatellite instability derive benefit from immune checkpoint inhibitors.CrossRefPubMed
37.
38.
Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–310.CrossRefPubMed
39.
Lievre A et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–5.CrossRefPubMed
40.
De Roock W et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594–603.CrossRefPubMed
41.
Inatomi O et al. Regulation of amphiregulin and epiregulin expression in human colonic subepithelial fibroblasts. Int J Mol Med. 2006;18(3):497–503.PubMed
42.
Khambata-Ford S et al. Expression of epiregulin and amphiregulin and K-ras status predict disease control in metastatic colorectal cancer patients treated with cetuximab. JCO. 2007;25(22):3230–7.CrossRef
43.
Jacobs B et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. JCO. 2009;27(30):5068–74.CrossRef
44.
Pentheroudakis G et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer. 2013;13(49):1–12.
45.
Douillard JY, Rong A, Sidhu R. RAS mutations in colorectal cancer. N Engl J Med. 2013;369(22):2159–60.CrossRefPubMed
46.
Segelov E, et al. The AGITG ICECREAM Study: The irinotecan cetuximab evaluation and cetuximab response evaluation amongst patients with a G13D mutation—analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. European Cancer Congress 2015; 32LBA.
47.
Misale S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–6.PubMedPubMedCentral
48.
Siena S et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101(19):1308–24.CrossRefPubMedPubMedCentral
49.
Siena S, et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients: The HERACLES trial. J Clin Oncol 33, 2015 (suppl; abstr 3508).
50.
51.
De Roock W et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62.CrossRefPubMed
52.
Yang H et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 2012;72(3):779–89.CrossRefPubMed
53.•
Prahallad A et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–3. This elegant research showed on a molecular basis that treatment of BRAF mutant CRC with vemurafenib alone resulted in ligand-dependent feedback activation of EGFR and consequent downstream AKT activation, which could be switched off with the use of combined EGFR and BRAF inhibition.CrossRefPubMed
54.
55.
56.
Di Renzo MF et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res. 1995;1(2):147–54.PubMed
57.
Fumagalli D et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 2010;10:101.CrossRefPubMedPubMedCentral
58.
Vassal G et al. Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: the French Mational AcSé Program. Eur J Cancer. 2015;51(S3):S715.CrossRef
59.
Van Schaeybroeck S et al. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep. 2014;7(6):1940–55.CrossRefPubMed
60.
Soda M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.CrossRefPubMed
61.
Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795(1):37–52.PubMed
62.
Solomon BJ et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77.CrossRefPubMed
63.
64.
Aisner DL et al. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res. 2014;12(1):111–8.CrossRefPubMedPubMedCentral
65.
66.
Di Narzo AF, et al. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data. J Natl Cancer Inst, 2014. 106(10).
67.
Gray RG et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29(35):4611–9.CrossRefPubMed
68.
Kennedy RD et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol. 2011;29(35):4620–6.CrossRefPubMed
69.
Salazar R et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29(1):17–24.CrossRefPubMed
70.
71.
Schlicker A et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics. 2012;5:66.CrossRefPubMedPubMedCentral
72.••
Guinney J et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6. This paper combines gene-expression data from more than 4000 patients to derive the first consensus molecular subtypes for colorectal cancer.CrossRefPubMedPubMedCentral
73.
Gourley C et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol. 2014;32:5s. suppl; abstr 5502.CrossRef
74.••
Kaplan R et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol. 2013;31(36):4562–8. Description of a new approach to trial design that links novel treatment evaluation with the concurrent evaluation of a biomarker within a confirmatory phase II/III trial setting. The statistical and methodological concepts underpinning this approach are described and applied to the FOCUS4 trial currently using this approach in advanced CRC.CrossRefPubMedPubMedCentral
75.
Schmoll H et al. MODUL—a multicentre randomised clinical trial of biomarker-driven therapy for the 1st-line maintenance treatment of metastatic colorectal cancer: a signal-seeking approach. Ann Oncol. 2014;25(4):209.
76.
O’Dwyer P. The next generation of targeted therapy trials in colorectal cancer. Clin Adv Hematol Oncol. 2014;12(12):852–4.PubMed
77.
Folprecht G, et al. Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcolor platform., in 2015 Gastrointestinal Cancers Symposium. 2015: San Francisco. abstr 575
78.••
Gerlinger M et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92. This seminal paper demonstrated how intratumoral heterogeneity can lead to marked complexity of the tumour genomics landscape in primary and related metastatic sites and the consequent challenges to personalized medicine and biomarker development from single tumour biopsies. It also describes how this heterogeneity may promote tumour adaptation and therapeutic failure through Darwinian selection and evolutionary pressures.CrossRefPubMed
79.•
Vakiani E et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;30(24):2956–62. This was the first paper to investigate heterogeneity between primary colorectal cancers and their metastases, demonstrating relative concordance for the driver genomic mutations in metastatic colorectal cancer.CrossRefPubMedPubMedCentral
80.
81.
Crowley E et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–84.CrossRefPubMed
82.•
Spindler KLG et al. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012;18:1177–85. This study investigated the levels of cfDNA in plasma from patients with metastatic CRC during third-line treatment with cetuximab and irinotecan. They showed that KRAS analysis in plasma is a viable alternative to tissue analysis and that quantitative levels of cfDNA and plasma mutant KRAS levels were strongly correlated.CrossRefPubMed
83.
Experimental Cancer Medicine Centres (ECMC) Network and National Cancer Research Institute (NCRI) Biomarkers and Imaging Clinical Studies Group Cell-free DNA Consensus Meeting: Meeting report. 24th November, 2014.
Metadata
Title
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer
Authors
Donna M. Graham
Vicky M. Coyle
Richard D. Kennedy
Richard H. Wilson
Publication date
01-06-2016
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 3/2016
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-016-0312-y

Other articles of this Issue 3/2016

Current Colorectal Cancer Reports 3/2016 Go to the issue

Translational Colorectal Oncology (Y Jiang, Section Editor)

Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons

Molecular Biology (S Mainardi, Section Editor)

Understanding Epigenetics: an Alternative Mechanism of Colorectal Carcinogenesis

Personalized Medicine in Colorectal Cancer (D Cunningham and EC Smyth, Section Editors)

The Economics of Personalized Therapy in Metastatic Colorectal Cancer

Colorectal Cancer Hepatic Metastases (MA Choti, Section Editor)

Managing the Primary Tumor with Unresectable Synchronous Colorectal Metastases

Colorectal Cancer Hepatic Metastases (MA Choti, Section Editor)

Surgical Margin in Hepatic Resections for Colorectal Metastasis: Should We Care?

Personalized Medicine in Colorectal Cancer (D Cunningham and EC Smyth, Section Editors)

Extramural Venous Invasion (EMVI) and Tumour Regression Grading (TRG) as Potential Prognostic Factors for Risk Stratification and Treatment Decision in Rectal Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits